



Roundtable – “Reproductive and Developmental Toxicology”
XX Brazilian Congress of Toxicology – Goiania, Brazil Oct 8-11, 2017

Computational Modeling of Developmental Toxicity: *modeling with human pluripotent stem cells*

Thomas B. Knudsen, PhD
Developmental Systems Biologist
US EPA, National Center for Computational Toxicology
Chemical Safety for Sustainability Research Program
knudsen.thomas@epa.gov
[ORCID 0000-0002-5036-596x](#)

DISCLAIMER: The views expressed are those of the presenter and do not reflect Agency policy.




Prenatal Developmental Toxicity





- An *in vivo* protocol commonly used to test for prenatal developmental toxicity (OECD TG 414) assesses litters of pregnant rats or rabbits exposed during organogenesis.
- Guideline protocols designed for health-protective assessment based on fetal effects at relatively high dosing scenarios, but are animal-intensive and low-throughput.
- HTS *in vitro* bioactivity (ToxCast/Tox21) provide alternative testing paradigm although low diversity of assays for assessing prenatal effects <https://actor.epa.gov/dashboard/#Chemicals>
- ToxCast library (1065 chemicals) tested in a pluripotent H9 human embryonic stem cell metabolomics assay, EPA/NCCT contract EP-D-13-055 with Stemina Biomarker Discovery.

Workflow: 1065 chemicals from ToxCast phase I/II library

* Plate Maps



Virtual Plates



atrophy 2.6.1.13
urea
arginase
urea cycle, polyamine & pyrimidine synthesis.

Ornithine release
urea cycle, polyamine & pyrimidine synthesis.





$$TI = ORN/CYSS$$

Cystine utilization
glutathione synthesis, redox cycling.





Plate-level Controls

$n=1158$ DMSO, 581 MTX-, 580 MTX+ ($P < 0.05$ Mann-Whitney), 2069 two-lowest two concentrations for ToxCast



Targeted Biomarker


tcpl default at 3*BMAD
(**o/c < 0.76**) accurately
classifies negative/positive
reference controls.



Cell Viability

3*BMAD for (acb = 0.894)
indicates a hit for **>10.6%**
cell loss.

Methotrexate: example of tcpl readout for the targeted biomarker (o/c ratio)



ASSAY: AEID1691 (STEMINA_H9_ORNCYSSISnorm_RATIO_dn)

NAME: Methotrexate

CHID: 20822 CASRN: 59-05-2

SPID(S): TP0001302A08

M4ID: 18146613

HILL MODEL (in red):

	tp	ga	gw
val:	1.97	-1.08	3.96
sd:	0.0247	0.0229	1.06

GAIN-LOSS MODEL (in blue):

	tp	ga	gw	la	lw
val:	1.98	-1.08	3.92	0.721	3.48
sd:	0.0529	0.0226	1.08	35.1	171

	CNST	HILL	GNLS
AIC:	74.32	-52.43	-48.44
PROB:	0	0.88	0.12
RMSE:	1.1	0.07	0.07

MAX_MEAN: 1.98

MAX_MED: 1.96

BMAD: 0.134

ACB: 0.0588

HIT-CALL: 1

FITC: 41

AC50: 0.0828

FLAGS:

Performance vs DevTox Anchor


- 181 of 1065 chems (17%) gave a positive response for developmental toxicity prediction.
- Point of departure for biomarker (acb ~0.76) usually before loss of cell viability (acb ~11%).

TEST	ANCHOR	
	TP	FP
	FN	TN

TP	14
FP	1
FN	4
TN	11
n	30
Sensitivity	0.778
Specificity	0.917
Accuracy	83.3%
Mathew's cc	0.680
F1 score	0.47

Anchor	TI (μM)	Class
all-trans-Retinoic acid	0.003	TP
Cytarabine hydrochloride	0.054	TP
Methotrexate	0.059	TP
Diphenhydramine hydrochloride	0.588	TP
Thalidomide	1.267	TP
5-Fluorouracil	2.021	TP
Carbamazepine	2.294	TP
Busulfan	2.313	TP
Amiodarone hydrochloride	5.101	TP
Dexamethasone sodium phosphate	37.680	TP
Hydroxyurea	74.935	TP
Valproic acid	154.955	TP
MEHP	166.595	TP
Salicylic acid	513.436	TP
Rifampicin	2.464	FP
5,5-Diphenylhydantoin	1000000	FN
Boric acid	1000000	FN
Cyclophosphamide monohydrate	1000000	FN
Ethylene glycol	1000000	FN
1,2-Propylene glycol	246664	TN
Acrylamide	1000000	TN
Aspirin	1000000	TN
Butylparaben	1000000	TN
Caffeine	1000000	TN
D-Camphor	1000000	TN
Dimethyl phthalate	1000000	TN
Isoniazid	1000000	TN
Retinol	1000000	TN
Saccharin	1000000	TN
Sodium L-ascorbate	1000000	TN

Performance vs ToxRefDB fetal endpoints



Concordance model (rat & rabbit):

- 272 chemicals tested for prenatal DevTox in both species
- Positives = dLEL $\leq$ 125 mg/kg/d for fetal endpoints
- Negatives = no dLEL $\geq$ 1000 mg/kg/day

ToxRefDB_DEV


TP	9
FP	19
FN	15
<u>TN</u>	<u>103</u>
n	146
Sensitivity	0.375
Specificity	0.844
Accuracy	76.7%
Mathew's cc	0.206
F1 score	0.005

Combined Model



TP	27
FP	19
FN	24
<u>TN</u>	<u>118</u>
n	188
Sensitivity	0.529
Specificity	0.861
Accuracy	77.1%
Mathew's cc	0.404
F1 score	0.006

Example 1: anti-angiogenic compounds confirmed in rat WEC


AC50 (embryo lethal) = 21.2 μ M



TI = 10.48 μ M



TI = 0.017 μ M



AC50 (dysmorphogenesis) = 0.038 μ M


Ellis-Hutchings (2017) Reprod Toxicol.

Example 2: stereoisomer pair resolved by STM but not animal studies




Fluazifop-butyl

69806-50-4 | DTXSID3034612 ⓘ

ⓘ Searched by Integrated Source Name: Found 1 result for 'fluazifop butyl'.



Rat dLEL (5 mg/kg/day)
Rabbit dLEL (50 mg/kg/day)
STM – not active




Fluazifop-P-butyl

79241-46-6 | DTXSID0034855 ⓘ

ⓘ Searched by Approved Name: Found 1 result for 'fluazifop-p-butyl'.





Rat dLEL (5 mg/kg/day)
Rabbit dLEL (50 mg/kg/day)
STM – TI = 24 µM



Example 3: endothelin receptor system (EDNR) is missed


- Several STM-positives hit EDNRs with submicromolar AC50s; strongest were Fandosentan (ETA antagonist) and MK-547 (probably ETB antagonist) but neither were STM-positive.
- Pharmacologic antagonists phenocopy *Ednra*-nullizygous (craniofacial/cardiac neural crest) and *Ednrb*-nullizygous (enteric neural crest) mice [Clouthier et al. 1998; Puffenberger et al. 1994; Spence et al. 1999].



Fandosentan

hETA = 0.042 μ M

STM = inactive (10 μ M)



MK-547

hETB = 0.0002 μ M

STM = inactive (20 μ M)

Machine-learning: pathway sensitivity against 337 biochemical targets in ToxCast

NVS ASIDs selected from
invitroDB v2 (June, 2017)

Filter NVS+ by AC50 cutoffs
(50 nM, 20 nM, 10 nM)

Feature selection with Scikit
(Python) classification
ANOVA 40th percentile

Build logistic regression model based on STM+ (1) and STM- (0) calls

AD score (weighted NVS
potency and discretized
targeted biomarker)

NIH_DAVID annotation: functional clusters

Strongest (-) enrichment clusters


[illegible]

DRD2	dopamine receptor D2(DRD2)
DRD1	dopamine receptor D1(DRD1)
Cacna1b	calcium voltage-gated channel subunit alpha1 B(CACNA1B)
Htr1a	5-hydroxytryptamine receptor 1A(HTR1A)
TACR2	tachykinin receptor 2(TACR2)
Adra1b	adrenoceptor alpha 1B(ADRA1B)
HTR7	5-hydroxytryptamine receptor 7(HTR7)
CHRM3	cholinergic receptor muscarinic 3(CHRM3)
Htr4	5-hydroxytryptamine receptor 4(HTR4)
BACE1	beta-secretase 1(BACE1)
EDNRA	endothelin receptor type A(EDNRA)
ESR1	estrogen receptor 1(ESR1)
RARA	retinoic acid receptor alpha(RARA)
PGR	progesterone receptor(PGR)
Ar	androgen receptor(AR)
NR1I2	nuclear receptor subfamily 1 group I member 2(NR1I2)

Developmental Systems Biology & Systems Toxicology

181 of 1065 ToxCast chemicals
(17%) exposure-based prediction
of developmental toxicity in STM
H9 stem cell model.

bioactivity profiles



Special Thanks

Todd Zurlinden – NCCT

Kate Sali – NCCT

Richard Judson - NCCT

Nathan Rush –NCCT

Parth Kothiya – NCCT

Nancy Baker – Leidos / NCCT

Richard Spencer – ARA / EMVL

Keith Houck -NCCT

Jessica Palmer – Stemina



Tox21 cross-partner project with NIH/NTP (N Kleinstreuer) and FDA/NCTR (A Lumen)

http://www2.epa.gov/sites/production/files/2013-08/documents/virtual_tissue_models_fact_sheet_final.pdf